The Maudsley Staging Method as predictor of electroconvulsive therapy effectiveness in depression

Acta Psychiatr Scand. 2018 Dec;138(6):605-614. doi: 10.1111/acps.12962. Epub 2018 Oct 1.

Abstract

Objective: To investigate the potential role of the Maudsley Staging Method (MSM) in the prediction of electroconvulsive therapy (ECT) outcome in severely depressed adults.

Method: Between August 2015 and August 2017, 73 consecutive patients with a major depressive episode (DSM-IV-TR) scheduled for ECT were recruited. Prior to their first ECT session, the MSM was completed to assess the level of therapy resistance. To determine the reduction in depression severity and response and remission rates, symptom severity was assessed at baseline and within one week after the last ECT session using the 17-item Hamilton Depression Rating Scale (HDRS17).

Results: The percentage of symptom reduction following ECT was best predicted by the MSM episode duration and depression severity factors (R2 completer sample 0.24). Episode duration alone was the best predictor of remission (area under the ROC curve for completers: 0.72). Adding age to the models increased their predictive capacity.

Conclusion: An adapted version of the MSM gauging shorter episode duration, more severe depressive symptoms and older age is significantly associated with ECT effectiveness in adults with severe recurrent depression and is thus highly suitable for use in clinical practice, promoting the shared treatment decision-making process.

Trial registration: ClinicalTrials.gov NCT02562846.

Keywords: decision-making; electroconvulsive therapy; major depressive disorder.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Depressive Disorder, Major / therapy*
  • Depressive Disorder, Treatment-Resistant / therapy*
  • Electroconvulsive Therapy / methods*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care / methods*
  • Remission Induction
  • Severity of Illness Index
  • Time Factors

Associated data

  • ClinicalTrials.gov/NCT02562846